...
首页> 外文期刊>International archives of allergy and immunology >Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: What differentiates patients with and without underlying chronic spontaneous urticaria
【24h】

Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: What differentiates patients with and without underlying chronic spontaneous urticaria

机译:多种非甾体类抗炎药诱发的皮肤疾病:区分有无潜在慢性自发性荨麻疹的患者

获取原文
获取原文并翻译 | 示例

摘要

Background: Multiple nonsteroidal anti-inflammatory drug (NSAID) cutaneous reactors may be otherwise normal or have underlying chronic spontaneous urticaria (CSU). This study compared these two phenotypes of NSAID-hypersensitive subjects. Methods: A total of 97 multiple NSAID reactors underwent oral challenges with paracetamol, etoricoxib and tramadol. Atopic status was investigated in all patients, and autoreactivity was ascertained in some cases as well. Otherwise normal multiple NSAID reactors were reevaluated after 1-5 years in order to detect their proneness to CSU. Results: At the first visit, 41 patients had CSU and 56 had multiple NSAID intolerance without any underlying cutaneous disease. Altogether, 22, 10 and 6% of patients did not tolerate paracetamol, etoricoxib and tramadol, respectively, on oral challenge. Intolerance to these alternative drugs showed a strong association (p < 0.01 with all combinations). The two subgroups of patients did not show any difference in terms of mean age, gender distribution, prevalence of atopic diseases, prevalence of single offending NSAIDs and prevalence of intolerance to paracetamol, etoricoxib or tramadol on oral challenge. In all, 20% of multiple NSAID reactors without CSU at presentation developed CSU between 6 months and 5 years after the initial clinical evaluation. Conclusions: Multiple NSAID cutaneous reactors with or without CSU seem identical from a clinical point of view, and some of the latter group show a propensity to acquire the former phenotype over time. A subset of patients apparently identical to the general population of multiple NSAID reactors also react to drugs exerting little or no cyclooxygenase-1 enzyme inhibition and might represent a distinct phenotype of NSAID-hypersensitive patients possibly characterized by a different underlying pathogenesis.
机译:背景:多种非甾体类抗炎药(NSAID)皮肤反应器可能正常,或具有潜在的慢性自发性荨麻疹(CSU)。这项研究比较了NSAID过敏性受试者的这两种表型。方法:总共97个多个NSAID反应器接受对乙酰氨基酚,依托昔布和曲马多口服攻击。对所有患者的特应性状况进行了调查,在某些情况下也确定了自身反应性。否则,要在1-5年后重新评估正常的多个NSAID反应堆,以检测其倾向于CSU的可能性。结果:第一次就诊时,有41例CSU患者和56例具有多种NSAID不耐症,而没有任何潜在的皮肤疾病。总共有22、10和6%的患者在口服刺激后分别不耐受扑热息痛,依托昔布和曲马多。对这些替代药物的不耐受性显示出很强的关联性(所有组合的p <0.01)。两组患者在平均年龄,性别分布,特应性疾病的患病率,单发性非甾体抗炎药的患病率以及对口服对乙酰氨基酚,依托考昔或曲马多的耐受性患病率方面均无差异。总体而言,在初次临床评估后的6个月至5年之间,有20%的多个不带CSU的NSAID反应堆都发展了CSU。结论:从临床角度来看,无论有无CSU的多个NSAID皮肤反应器似乎是相同的,后一组中的一些显示出随着时间的流逝获得前一种表型的倾向。显然与多个NSAID反应器的总体人群相同的一部分患者对发生环氧化酶1酶抑制作用很小或没有的药物也有反应,并且可能代表了NSAID过敏症患者的独特表型,其特征可能在于潜在的发病机制不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号